Advances in machine learning centered on deep learning, the increasing performance of GPUs, the sophistication of information infrastructure, and the expanding utilization of big data have significantly heightened expectations for AI. I have promoted medical device development and drug discovery through AI analysis of medical big data, and has achieved multiple results implemented clinically after obtaining regulatory approval. This presentation will introduce these achievements and the latest technological and implementation status.

In pharmaceutical supply chain management (SCM), data utilization including “externally provided data” has been advanced, and SCM visibility and AI-enabled sales forecasting have been established to a practical level. However, challenges remain in data completeness and timeliness. Going forward, downstream data closer to patients will be complemented and enhanced through digital technologies. By redesigning the end‑to‑end pharmaceutical supply chain through improved forecasting and supply‑scheme optimization, we aim not only to drive broader transformation but also to ensure the stable and reliable delivery of the medicines patients need.

We welcome Mr. Sezaki from UCB Japan—who has led digital transformation across both domestic and global pharmaceutical organizations—as our panelist. Together, we will discuss how effective omnichannel operations can enable smoother, more meaningful communication with healthcare professionals. What barriers are preventing real progress in marketing strategy and MR activity transformation? Joined by our Web Director, who has extensive expertise in CRM technology, data strategy, and content design, we will explore practical, actionable solutions to bridge the gap between vision and reality. 

Pharmaceutical marketing is entering a new “ecosystem era,” where companies, physicians, and patients are increasingly connected through advancing technologies. This lecture provides a broad view of how IT, AI, and data are reshaping industry structures, outlining the future shift from SOV-based approaches to behavior change and ultimately ecosystem optimization. It then offers clear guidance on how pharmaceutical companies should position themselves within emerging ecosystems and what strategic choices they must make to succeed in this new landscape.

This session explores how AI drives digital transformation in the pharmaceutical industry, addressing process efficiency, reducing reliance on individual expertise, and alleviating workloads. Learn actionable insights and real-world examples to revolutionize manufacturing while maintaining safety and quality standards.

TriNetX is a global federated network connecting healthcare organizations and life sciences companies to accelerate the development of new therapies through research using real-world data (RWD). Leveraging RWD from 300 million patients and a cloud-based clinical research and trial platform, TriNetX enables real-world evidence generation and trial optimization. In Japan, the network is rapidly expanding with more participating institutions and accessible data.

To further advance digital transformation, a key challenge lies in how to safely and securely utilise personal and confidential information—such as research and development data and clinical data—within the healthcare and pharmaceutical sectors. This presentation will explain practical data utilisation approaches for pharmaceutical companies and healthcare organisations, drawing on leading European examples that achieve data sharing even under strict regulations. These approaches leverage Personalised Electronic Trusts (PETs) and digital IDs. 

The success of a new drug launch strategy depends on understanding the market as a structure. This session introduces an approach that integrates secondary research (RWD) with primary insights to frame the market through Why → Where → Who. As AI evolves, marketers and strategists must determine how to use AI effectively and where human judgment should guide decisions. I will share practical perspectives to support launch planning in this new era.

Electronic health records contain rich information not captured in claims data, including lab results, clinical notes, and physicians’ clinical judgments. TXP Medical structures these deep clinical data and, together with specialist physicians, supports study design and outcome definition to enable pharmaceutical companies to conduct high-precision and highly feasible database research. This approach accelerates real-world evidence generation and allows robust analysis across multiple diseases. In this session, we will introduce the new value created by combining deep EHR data with medical expertise. 

This presentation introduces “QAI,” an AI-powered SaaS platform developed by a University of Tokyo–originated startup to support document-intensive workflows in the pharmaceutical and healthcare industries. Covering clinical development, regulatory affairs, quality assurance, manufacturing, marketing, and hospital operations, the session demonstrates how AI enables efficient document creation, review, search, training, and knowledge utilization through real-world use cases. It also discusses how large language models (LLMs) are transforming regulated industries and outlines future directions for AI adoption in pharmaceutical and healthcare domains.

As pharmaceutical companies advance their digital transformation, robust design and operation of digital disease awareness initiatives are becoming essential to delivering truly patient-centric care. This session will share insights from projects: Asahi Kasei Pharma’s osteoporosis program “honeken,” Kyowa Kirin’s FGF23-related hypophosphatemic rickets/osteomalacia project “Kurukotsu Hiroba,” and Vantive's chronic kidney disease platform “Toseki-Byoin.com.” Focusing on patient-journey–based information design and integration with hospital search services, we will highlight practical lessons and considerations for future initiatives.

As the two pillars of building competitiveness in the digital age, the first is to create new value from unstructured qualitative data and enhance the quality of strategic planning. The second is to innovate existing business structures and strengthen organizational execution capabilities. By integrating "insight creation" and "operation innovation," we present a practical approach tailored to the pharmaceutical industry to establish a foundation for sustainable growth.

This seminar provides a structured overview of the key perspectives that pharmaceutical companies should consider when evaluating Real-World Data (RWD) for utilization. Amid the growing diversity of RWD sources, we will explain how to identify the most suitable data for your objectives and how to effectively differentiate their use. From the standpoint of a health data science expert, the session will offer practical insights and actionable guidance for real-world application.

Pharmaceutical companies are increasingly leveraging data across multiple functions, including Medical Affairs, Marketing, and Clinical Development. However, differences in data definitions and intended use often create challenges for cross-functional collaboration and data integration.In this presentation, drawing on practical experience in data science and the utilization of patient and market data in the Japanese market, I will discuss key perspectives, common challenges, and real-world solutions for enabling effective cross-functional data utilization.

FRONTEO’s proprietary natural language processing AI engine, “KIBIT”, enables non-continuous discovery by identifying relationships that are not described in existing literature. This contrasts with conventional continuous discovery methods that rely on direct, sequential connections. Building upon this unique capability, we have developed the “Drug Discovery AI Factory (DDAIF)”—a comprehensive solution designed to support the identification of highly novel drug targets and indications (DR, LCM) and the others. In this presentation, we will provide an overview of the DDAIF solution and share findings from an in vitro study that utilized DDAIF to identify novel therapeutic targets for pancreatic cancer.

Advances in pharmaceuticals have expanded treatment options even in the field of rare diseases. However, due to the very nature of rare diseases, it is often difficult for individual clinical settings to fully grasp the overall picture of the diagnostic process and post-diagnosis treatment. In this lecture, using several rare diseases as examples, we provide an overview of the patient journey—including the periods before and after diagnosis—through the use of real-world data (RWD), and organize the associated disease burden. We will share the significance of utilizing RWD in the rare disease field and discuss its implications for drug development and evidence generation.

This session demonstrates how AI Agents can accelerate research and decision-making in Life Sciences through a live demo of Patsnap’s Eureka Life Science. The presentation covers practical use cases including competitive intelligence, patent analysis, lead compound evaluation, antibody–antigen analysis, and Markush candidate generation. By showcasing a data-driven, AI-powered workflow, the session highlights how researchers and strategists can rapidly gain actionable insights and streamline complex analyses across the drug discovery process.

This presentation introduces an approach that enhances the precision and efficiency of MR activities by combining dynamic targeting—powered by machinelearning–based data accumulation and analysis to recommend the optimal frequency and timing of engagements for each healthcare professional—with an AI Agent that integrates internal and external information to reduce search time and improve the quality of medical information provision by MRs. 

The pharmaceutical industry is moving beyond isolated AI pilots toward AI-first transformation that redefines operations, organizations, and workforce models. This session provides an end-to-end view of AI adoption across the pharma value chain, including drug discovery, development, PV, MA, and corporate functions. Based on industry-wide insights and IBM’s Client Zero experience, where IBM applies AI to its own operations, the speaker presents practical and executable approaches for moving from vision toward execution.

In pharmaceutical manufacturing process development, there has been growing attention in recent years toward approaches utilizing Modeling & Simulation (M&S), with expectations for shortening development periods and improving process robustness. In this presentation, we will introduce case studies of M&S applications to therapeutic antibody process development at our company, and report on enhanced understanding of bioprocess and improved development efficiency through integrated use of machine learning and mechanistic models.

In the first part of this session, we address the ongoing challenges in pharmaceutical marketing, where essential medical information does not always reach physicians in a timely or effective manner. As physicians increasingly curate trusted, high-quality information from digital platforms and academic meetings, the role of reliable medical information channels has become more critical than ever. In the second part, we introduce InsighTCROSS, an AI-driven system designed to optimise sales and marketing activities. We also present its latest feature, EarlyScripters, which enhances the system’s ability to detect, characterise, and understand influential early adopters, enabling more targeted and efficient engagement strategies.

Patient information searches have become widely dispersed, spanning search engines, generative AI, social media searches, and medical Q&A platforms. Amid this shift, disease awareness sites must evolve beyond mere “web pages” to become more easily discoverable by patients. This seminar will introduce the latest practical strategies, covering AI-era optimized content design, digital pathways tailored to the patient journey, and initiatives connecting AI search. 

Driving behavioral change requires identifying a doctor's "decision-making points" in clinical settings. This session reveals insights from the slide viewing logs of 74,000 physicians, visualizing the unconscious information-seeking process often missed by traditional surveys. We analyze how clinical questions are resolved in real-time. Attendees will learn methods to significantly improve product launch accuracy by utilizing unbiased, real-world behavioral data to uncover deep insights into physician psychology.

FPT Software develops medical systems globally from its Vietnam base, serving North America, the EU, and ASEAN countries. We address differences in national medical reimbursement and insurance systems, while also considering global medical data standardization. Our expertise covers a wide range: from medical device software and real-world data platforms to both SaMD and non-SaMD development. We also present cutting-edge case studies in generative AI applications for healthcare. These experiences demonstrate our ability to deliver advanced, compliant healthcare solutions tailored to various international regulatory and market requirements.

In this session, we will present methods for the safe and secure enterprise adoption of AI and AI agents, alongside the latest use cases. We plan to introduce examples across several key business areas, including R&D, quality control for regulatory compliance, and general administrative operations. 

We provide an integrated solution that accelerates the entire process of physician behavior change—from awareness to prescription—and visualizes its outcomes. By understanding each physician's status at every stage of behavior change, identifying bottlenecks, and delivering relevant information, we build a system that streamlines the physician's decision-making process. Our solution accurately captures the transformation process—which was difficult to grasp with conventional approaches—enabling us to visualize effectiveness and improve reproducibility.

NEC has long contributed to the digital transformation of healthcare institutions, including recent initiatives such as providing electronic medical record systems equipped with Japan-developed generative AI. We have been driving medical DX across various domains. In addition, to enable more efficient drug discovery, clinical development, and clinical trials, NEC is leveraging the medical data expertise and AI technologies cultivated over many years in clinical settings. We are working to deliver services that make effective use of RWD. In this session, we will introduce NEC’s ongoing initiatives aimed at realizing an integrated clinical trial ecosystem.

As safety management across the drug lifecycle gains importance, PV teams face challenges such as talent development, diverse information sources, manual workloads, and increasingly complex evaluation and prediction. This presentation introduces two solutions to improve safety-data quality: (1) AE BridgeX, which automatically converts diverse unstructured data into E2b format; and (2) PV Virtual Assistant, which leverages the safety database as a knowledge base to support case search, summarization, and review—explained together with practical usage scenarios.

Even when patients receive information, their behavior often doesn’t change. Many patient-engagement and screening initiatives face this challenge. This session introduces an approach that uses PHR-based interventions and real-world data to quantify behavior change. By visualizing shifts in consultation and prescription rates, opportunities for improvement become clear. A disciplined process of forming hypotheses, validating with data, and refining actions—a scientific discipline for continuous improvement—can elevate patient-engagement and screening initiatives to the next stage.

In pharmaceutical marketing, rapid response to customer needs and strict adherence to legal requirements are essential. This session introduces the latest trends and practical applications of AI-driven content creation. AI enables faster, more cost-efficient production and validation of materials while maintaining regulatory compliance. We will demonstrate how AI streamlines workflows, accelerates content volume, and supports tasks such as format transformation and segmentation-specific variations. These approaches help establish competitive product advantages by improving both speed and quality. 

In 2026, competitive advantage depends on integrating AI into education. We share case studies of AI Roleplay using the latest LLM technology. Unlike traditional scenarios, we verify the learning effects of natural dialogue and instant feedback. We discuss the "AI x Human" hybrid training model that maximizes sales power while reducing workload, along with implementation tips. 

Maximizing product value requires genuine improvement in patient experience. In this session, we will introduce a new support model for pharmaceutical companies through the collaboration between LunaLuna, a women-centered platform with over 22 million downloads, and Pharumo, which connects with more than 10,000 pharmacies. Leveraging these strong platforms, we will discuss how to engage with patients in their daily lives and drive meaningful adherence and appropriate use—presenting concrete approaches for next-generation, accompanied marketing.

Omnichannel has become a core strategy in pharmaceutical marketing, yet few organizations can clearly explain how their initiatives influence physicians’ prescribing decisions. This presentation argues that the real challenge lies in confusing customer touchpoint optimization with decision-making design. Drawing on examples of treatment dilemmas in oncology and rare diseases, it explores how prescribing decisions are shaped under clinical uncertainty. Reinterpreting Rita McGrath’s arena theory for healthcare, the session proposes a strategic shift—from competing across channels to competing in the “Decision Arena,” where treatment choices are ultimately made.

Promoting digital transformation (DX) in pharmaceutical R&D, which involves complex and diverse processes, is of critical importance. Based on our recent survey of pharmaceutical companies in Japan, this presentation examines the current state, challenges, and expectations surrounding DX in R&D. While there are high expectations for shortening development timelines and improving productivity, issues such as cross-departmental collaboration, data governance, and AI expertise remain. We present these findings alongside an analysis of the required human capabilities, and explore the potential of DX to drive further evolution and new value creation in pharmaceutical R&D.

We have shifted from acquiring real-world data (RWD) to selecting and mastering its use. Drug discovery, clinical development, commercial operations, business development... How is the value of real-world data being generated across the pharmaceutical value chain? As AI technology advances, we also want to consider the role of human expertise within this landscape.

In the pharmaceutical industry, real-world data are increasingly used across a wide range of activities, including drug discovery and evidence generation. In this presentation, I will introduce how real-world data are leveraged in dementia, one of Eisai’s key therapeutic areas, and demonstrate how data science can contribute to advancing dementia research.

Antaa fosters a culture where doctors support each other under the mission "Connecting Medicine, Connecting Lives." This session explores this high-energy community of 74,000 physicians and our data vision integrating learning with practice through JMDC collaboration. We propose a next-generation marketing model that moves beyond one-way information delivery. Learn how to co-create value as a true partner in clinical learning, supporting the ecosystem while driving meaningful engagement.

Utilizing unstructured text data, such as inquiry records and daily reports, has long challenged pharmaceutical companies. Yet, these sources conceal the "true voices" of doctors and patients—critical for understanding treatment needs and improving QOL.

This seminar explores cutting-edge methods for mining actionable insights from massive text datasets, illustrated by real-world case studies. Join us to learn practical approaches that transform tacit knowledge into explicit strategies, ultimately driving true Patient Centricity.

Epistra has supported over 60 experimental optimization projects for pharmaceutical and biotech companies using its proprietary AI solution, Epistra Accelerate. This presentation covers real-world achievements including world-class yields in microbial fermentation and the impact of autonomous experimentation systems combining AI and robotics on cell manufacturing for regenerative medicine. We also discuss future directions including the AI Custom Media Development Service co-created with Shimadzu Group. 

In recent years, the importance of data integrity and ALCOA+ has become increasingly recognized, but are these principles fully ensured for the analytical instrument data you currently manage? This presentation explains the advantages of a cloud archive solution that is easy to implement and offers a high cost-benefit ratio, along with how our services can help you take the first step toward deployment.

Utilizing Generative AI for commercial function is the biggest challenge for all pharmaceutical companies. In this session, Generative AI for omnichannel management will be discussed to maximize return on investment for omnichannel.

Mediwill, the organizer of disease awareness initiatives and the Pharma Innovation EXPO, presents a session examining the future of digital marketing in the generative AI-driven DX era. This session engages attendees in exploring disease awareness case studies, including osteoporosis, dialysis for kidney failure, and rare diseases, alongside the latest DX solutions highlighted by Expo exhibitors. Participants will gain insights into emerging trends and strategic opportunities for leveraging digital marketing to drive innovation and enhance healthcare communication.